HIV-2 gp36

Synthetic HIV-2 gp36
Cat. No.
BT24258
Source
Synthetic.
Synonyms
Appearance
Sterile filtered colorless clear solution.
Purity
Greater than 95.0% as determined by HPLC.
Usage
THE BioTek's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
Shipped with Ice Packs
In Stock

Description

HIV-2 gp36 is full length chemically synthesized polypeptide sequence of HIV-2 envelope immunodominant regions.

Product Specs

Introduction
HIV-1 and HIV-2 exhibit distinct RNA packaging mechanisms. HIV-1 indiscriminately binds to suitable RNA, while HIV-2 preferentially targets mRNA responsible for Gag protein synthesis. This selective binding in HIV-2 limits its mutation rate compared to HIV-1. Both HIV-1 and HIV-2 share common transmission routes through exposure to infected bodily fluids such as blood, semen, vaginal secretions, and tears. However, HIV-2 infection progresses at a slower rate, leading to delayed immunodeficiency development. In the initial stages, HIV-2 demonstrates lower infectivity compared to HIV-1, but its infectiousness increases as the disease progresses. Key distinctions between the two viruses encompass HIV-2's reduced pathogenicity, enhanced immune system control, and a degree of independence from CD4 cells for replication. Despite significant differences in their genomic sequences and phenotypic characteristics, HIV-1 and HIV-2 envelopes share structural similarities. Both viruses possess membrane-anchored proteins that assemble into six-helix bundles at their ectodomain's N-terminal and C-terminal regions, a common feature observed in various viral and cellular fusion proteins, contributing to the fusion process. Although HIV-1 gp41 helical regions form more stable six-helix bundles compared to their HIV-2 counterparts, HIV-2 fusion occurs at a lower temperature threshold (25°C), does not require calcium ions, remains unaffected by cytochalasin B treatment on target cells, and exhibits independence from target membrane glycosphingolipid composition.
Description
HIV-2 gp36 is a chemically synthesized polypeptide that represents the full-length sequence of immunodominant regions within the HIV-2 envelope protein.
Physical Appearance
The product appears as a clear, colorless solution that has been sterilized through filtration.
Formulation
The product is supplied as a solution with a concentration of 1 mg/ml in water (H2O).
Purity
The purity of the product is greater than 95.0% as determined by High-Performance Liquid Chromatography (HPLC) analysis.
Stability
For optimal stability, HIV-2 gp36 should be stored at -18°C. While it can remain stable at 4°C for up to one week, it is crucial to avoid repeated freeze-thaw cycles.
Applications
HIV-2 gp36 antigen is a versatile reagent suitable for various immunological assays, including ELISA and Western blots. Its high sensitivity makes it an excellent antigen for the early detection of HIV seroconverters with minimal specificity issues.
Source
Synthetic.
Specificity
Immunoreactive with all sera of HIV-2 infected individuals.

Product Science Overview

Introduction

HIV-2 is a type of Human Immunodeficiency Virus (HIV) that is less prevalent and generally less pathogenic than HIV-1. The envelope glycoproteins of HIV-2 play a crucial role in the virus’s ability to infect host cells. One of these glycoproteins is gp36, which is a transmembrane protein involved in the fusion of the virus with the host cell membrane.

Structure and Function

The HIV-2 envelope is composed of two main glycoproteins: gp125 and gp36. These proteins are linked by noncovalent bonds and are embedded in a lipid bilayer derived from the host cell’s cytoplasmic membrane . The gp125 protein is responsible for binding to the host cell receptors, while gp36 mediates the fusion of the viral and host cell membranes .

Gp36 is a 36 kDa protein that is produced as part of a larger polyprotein precursor. This precursor undergoes glycosylation in the Golgi apparatus and is then cleaved by furin in the trans-Golgi network to produce the mature gp36 protein . The cleavage positions the fusion peptide at the N-terminus of gp36, priming it for fusion activation .

Synthetic HIV-2 gp36

Synthetic HIV-2 gp36 refers to the recombinant form of the gp36 protein, which is produced using various biotechnological methods. This synthetic form is often used in research and diagnostic applications. For instance, synthetic gp36 can be produced in Escherichia coli and is often fused to other proteins, such as beta-galactosidase, to facilitate its purification and detection .

The synthetic gp36 protein retains the immunodominant regions of the natural protein, making it useful for studying the immune response to HIV-2 and for developing diagnostic assays . It is also used in the development of vaccines and therapeutic agents aimed at preventing or treating HIV-2 infection .

Applications and Importance

The study of synthetic HIV-2 gp36 is important for several reasons:

  1. Vaccine Development: Understanding the structure and function of gp36 can aid in the design of vaccines that elicit a strong immune response against HIV-2.
  2. Diagnostic Tools: Synthetic gp36 is used in various diagnostic assays to detect HIV-2 infection. These assays are crucial for early diagnosis and management of the disease.
  3. Therapeutic Research: Research on gp36 can lead to the development of new therapeutic agents that target the fusion process of HIV-2, potentially inhibiting the virus’s ability to infect host cells.

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2024 Thebiotek. All Rights Reserved.